SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 ± bevacizumab (bev) versus mFOLFOX6+selective internal radiation therapy (SIRT) ± bev in patients (pts) with metastatic colorectal cancer (mCRC).

被引：8
|
作者：
Gibbs, Peter
Heinemann, Volker
Sharma, Navesh K.
Findlay, Michael P. N.
Ricke, Jens
Gebski, Val
Van Buskirk, Mark
Van Hazel, Guy A.
机构：
[1] Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia
[2] Univ Munich, Dept Internal Med 3, Munich, Germany
[3] Univ Munich, Klinikum Grosshadern, Ctr Comprehens Canc, D-80539 Munich, Germany
[4] Univ Maryland, Med Ctr, Baltimore, MD 21201 USA
[5] Univ Auckland, Canc Trials New Zealand, Auckland 1, New Zealand
[6] Univ Clin Magdeburg, Magdeburg, Germany
[7] NHMRC Clin Trials Ctr, Camperdown, NSW, Australia
[8] Data Reduct LLC, Chester, NJ USA
[9] Univ Western Australia, Perth, WA 6009, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.3502
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3502
引用
收藏
页数：1
相关论文
共 50 条
  • [21] FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the phase III TRIBE trial by GONO group.
    Falcone, Alfredo
    Cremolini, Chiara
    Masi, Gianluca
    Lonardi, Sara
    Zagonel, Vittorina
    Salvatore, Lisa
    Trenta, Patrizia
    Tomasello, Gianluca
    Ronzoni, Monica
    Ciuffreda, Libero
    Zaniboni, Alberto
    Tonini, Giuseppe
    Buonadonna, Angela
    Valsuani, Chiara
    Chiara, Silvana
    Carlomagno, Chiara
    Boni, Corrado
    Marcucci, Lorenzo
    Boni, Luca
    Loupakis, Fotios
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [22] A randomized, phase IIb study of sunitinib plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) versus bevacizumab plus mFOLFOX6 ns first-line treatment for metastatic colorectal cancer (mCRC); Interim results.
    Hecht, J. R.
    Yoshio, T.
    Mitchell, E. P.
    Dees, M. S., III
    Countouriotis, A. M.
    Maneval, E. C.
    Kretzschmar, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [23] Safety and efficacy of AMG 655 plus modified FOLFOX6 (mFOLFOX6) and bevacizumab (B) for the first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC)
    Saltz, L.
    Infante, J.
    Schwartzberg, L.
    Stephenson, J.
    Rocha-Lima, C.
    Galimi, F.
    Dillingham, K.
    Hsu, M.
    Wiezorek, J.
    Fuchs, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [24] Efficacy and safety of fruquintinib plus mFOLFOX6/FOLFIRI as first-line therapy in advanced metastatic colorectal cancer (mCRC).
    Zhou, Fuxiang
    Wang Wen-bo
    Xia, Ling
    Dai, Jing
    Wu, Han
    Yang, Lei
    Xiong, Zhiguo
    Gong, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 152 - 152
  • [25] Phase I study of first-line sunitinib (SU) plus modified FOLFOX6 (mFOLFOX6) in Japanese patients (pts) with metastatic colorectal cancer (mCRC)
    Hamaguchi, T.
    Yoshino, T.
    Ohtsu, A.
    Yamazaki, K.
    Shimada, Y.
    Kato, K.
    Yasui, H.
    Boku, N.
    EJC SUPPLEMENTS, 2009, 7 (02): : 340 - 340
  • [26] MFOLFOX6 plus CEDIRANIB VS MFOLFOX6 plus BEVACIZUMAB IN PREVIOUSLY UNTREATED METASTATIC COLORECTAL CANCER (MCRC): A RANDOMIZED, DOUBLE-BLIND, PHASE II/III STUDY (HORIZON III)
    Schmoll, H.
    Cunningham, D.
    Sobrero, A.
    Karapetis, C.
    Rougier, P.
    Koski, S. L.
    Barker, P.
    Mookerjee, B.
    Robertson, J.
    van Cutsem, E.
    ANNALS OF ONCOLOGY, 2010, 21 : 189 - 189
  • [27] Randomized Phase 2 Study Comparing Pathological Responses of Resected Colorectal Cancer Metastases after Bevacizumab with mFOLFOX6 or FOLFIRI (BEV-ONCO Trial)
    Baldin, Pamela
    Carrasco, Javier
    Beniuga, Gabriela
    Jouret-Mourin, Anne
    Demolin, Gauthier
    Roland, Sandrine
    D'Hondt, Lionel
    Vergauwe, Philippe
    Van Daele, Daniel
    Mailleux, Marie
    Sinapi, Isabelle
    De Cuyper, Astrid
    Bletard, Noella
    Massart, Brigitte
    Delos, Monique
    Castella, Marie-Laure
    van Maanen, Aline
    Van den Eynde, Marc
    CANCERS, 2022, 14 (05)
  • [28] COST-EFFECTIVENESS ANALYSIS OF PANITUMUMAB PLUS MFOLFOX6 VERSUS BEVACIZUMAB PLUS MFOLFOX6 FOR FIRST-LINE TREATMENT OF PATIENTS WITH WILD-TYPE RAS METASTATIC COLORECTAL CANCER
    Graham, C. N.
    Hechmati, G.
    Hjelmgren, J.
    De Liege, F.
    Lanier, J.
    Knoof, A.
    Knox, H.
    Barber, B.
    de Pouvourville, G.
    VALUE IN HEALTH, 2014, 17 (07) : A632 - A632
  • [29] Intergroup randomized phase III study of postoperative oxaliplatin, 5-fluorouracil and leucovorin (mFOLFOX6) vs mFOLFOX6 and bevacizumab (Bev) for patients (pts) with stage II/III rectal cancer receiving pre-operative chemoradiation
    Benson, Al Bowen
    Zhao, Fengmin
    Meropol, Neal J.
    Catalano, Paul J.
    Chakravarthy, Bapsi
    Flynn, Patrick J.
    Catalano, Robert B.
    Giantonio, Bruce J.
    Mitchell, Edith P.
    Haller, Daniel G.
    Leichman, Cynthia G.
    Petrelli, Nicholas J.
    Sinicrope, Frank A.
    Tepper, Joel E.
    Brierley, James D.
    Sigurdson, Elin R.
    Whittington, Richard M.
    O'Dwyer, Peter J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [30] Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for RAS Mutant Unresectable Colorectal Liver-Limited Metastases: The BECOME Randomized Controlled Trial
    Tang, Wentao
    Ren, Li
    Liu, Tianshu
    Ye, Qinghai
    Wei, Ye
    He, Guodong
    Lin, Qi
    Wang, Xiaoying
    Wang, Mingliang
    Liang, Fei
    Cui, Yuehong
    Xu, Jianmin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (27) : 3175 - +
12345